infusion reaction

infusion reaction

Any adverse reaction to a constituent administered intravenously, such as, an anaphylactic or anaphylactoid reaction to a monoclonal antibody.
See: transfusion reaction
References in periodicals archive ?
* The most common adverse reactions (reported in [greater than or equal to] 10% of patients) with POTELIGEO in the clinical trial were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%).
This was promptly followed by ustekinumab for 9 months but had to be discontinued because of primary inefficacy.Then, he was then on infliximab for a year, which again had to be terminated following an inadeguate response and a possible infusion reaction. All these therapies were prescribed at a different center.
Two patients experienced an infusion reaction and none developed antibodies to Factor Xa or Factor X or neutralizing antibodies to Andexxa.
The drug was well tolerated, with no opportunistic infections or tuberculosis, and the infusion reaction rate was below 2% (Arthritis Rheumatol.
Demographic, clinical symptoms, and infusion reaction data were recorded from the patients' charts.
* In controlled clinical trials, 71.2% of patients in the sipuleucel-T group developed an acute infusion reaction.
Extensive forearm deep vein thrombosis following a severe infliximab infusion reaction. Eur J Gastroenterol Hepatol 2004; 16: 941-2.
Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan) infusions.
These initial infusion reaction effects can be treated symptomatically and occur infrequently in subsequent infusions.
Also, if they don't have such a robust response, it probably means they have antibodies to pegylated uricase, which increases the risk of infusion reaction. In that case, "stop the drug," he said.
During an infusion reaction, early intervention may prevent serious side effects and death.